Name: Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Access and distribution
Published: 2026-09-21T21:39:21-04:00

Product information and disease description Product description Product information

Access and distribution

4 evidence topics · 4 sources

Allergist-first launch strategy

“As we prepare for a focused, allergist-first launch, if approved, we are moving with urgency to bring Anaphylm to the patients who need it most.” (opens the source at this quote in a new tab)

“our full attention will be to prepare for a focused, allergist-first launch of Anaphylm as quickly as possible, if approved by the FDA” (opens the source at this quote in a new tab)

Planned sales force size and prescriber targeting

“~75 SALES REPRESENTATIVES AT LAUNCH” (opens the source at this quote in a new tab)
“Engagement with priority allergists and pediatricians” (opens the source at this quote in a new tab)
“~8K Target HCPs” (opens the source at this quote in a new tab)
“Coverage metrics shown are based on the 75 representative planning scenario; final launch deployment is expected to range from 65–80 representatives” (opens the source at this quote in a new tab)

Patient support services and payer engagement

“Patient Support Services to Simplify Anaphylm Access” (opens the source at this quote in a new tab)
“Proactive Payer Engagement Supports Post-Approval Access Readiness” (opens the source at this quote in a new tab)

Out-licensing of commercialization rights outside the United States

“Continue to evaluate out-licensing opportunities for Libervant® in the U.S. and Anaphylm ex-U.S.” (opens the source at this quote in a new tab)